Mylan Laboratories Limited — Clopidogrel Exporter Profile
Indian Pharmaceutical Exporter · #10 for Clopidogrel · $4.3M export value · DGFT Verified
Mylan Laboratories Limited is the #10 Indian exporter of Clopidogrel with $4.3M in export value and 86 verified shipments. Mylan Laboratories Limited holds a 1.7% market share in Clopidogrel exports across 3 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.
Mylan Laboratories Limited — Clopidogrel Export Profile: Buyers & Destinations
Where Does Mylan Laboratories Limited Export Clopidogrel?
| Country | Value | Shipments | Share |
|---|---|---|---|
| FRANCE | $2.4M | 48 | 58.7% |
| ITALY | $1.6M | 37 | 40.1% |
| NETHERLANDS | $50.0K | 1 | 1.2% |
Mylan Laboratories Limited exports Clopidogrel to 3 countries. The largest destination is FRANCE accounting for 58.7% of Mylan Laboratories Limited's Clopidogrel shipments, followed by ITALY (40.1%) and NETHERLANDS (1.2%). These destinations reflect Mylan Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Clopidogrel from Mylan Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN ITALIA S.R.L., | ITALY | $700.0K | 14 |
| VIATRIS ITALIA S R L VIALE DELLE INDUSTRIE SNC | ITALY | $450.0K | 9 |
| CSP VIATRIS SANTE AT CSP- LAB, | FRANCE | $400.0K | 8 |
| CSP VIATRIS SANTE AT CSP LAB | FRANCE | $300.0K | 6 |
| M/S. CSP MYLAN SAS AT CSP LABO 274 | FRANCE | $250.0K | 5 |
| CSP MYLAN SAS AT CSP LABO 274 | FRANCE | $250.0K | 5 |
| CSP VIATRIS SANTE AT CSP- LAB | FRANCE | $250.0K | 5 |
| CSP MYLAN SAS AT CSP-LABO 274 | FRANCE | $200.0K | 4 |
| CSP | FRANCE | $200.0K | 4 |
| CSP MYLAN SAS AT CSP- LABO 274, | FRANCE | $150.0K | 3 |
Mylan Laboratories Limited supplies Clopidogrel to 19 buyers globally. The largest buyer is MYLAN ITALIA S.R.L., (ITALY), followed by VIATRIS ITALIA S R L VIALE DELLE INDUSTRIE SNC (ITALY) and CSP VIATRIS SANTE AT CSP- LAB, (FRANCE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Clopidogrel Export Value and How Much Does Mylan Laboratories Limited Contribute?
India exported $133.2M worth of Clopidogrel through 6,037 shipments from 416 suppliers to 137 countries, serving 1,234 buyers globally. Mylan Laboratories Limited contributes $4.3M to this total, accounting for 1.7% of India's Clopidogrel exports. Mylan Laboratories Limited ships Clopidogrel to 3 countries through 19 buyers.
What Is the Average Shipment Value for Mylan Laboratories Limited's Clopidogrel Exports?
Mylan Laboratories Limited's average Clopidogrel shipment value is $50.0K per consignment, based on 86 shipments totaling $4.3M. The largest destination is FRANCE (58.7% of Mylan Laboratories Limited's Clopidogrel exports).
How Does Mylan Laboratories Limited Compare to Other Indian Clopidogrel Exporters?
Mylan Laboratories Limited ranks #10 among 416 Indian Clopidogrel exporters with a 1.7% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($36.4M), ZENTIVA PRIVATE LIMITED ($19.0M), DR.REDDY'S LABORATORIES LTD ($14.3M). Mylan Laboratories Limited processed 86 shipments to 3 destination countries.
What Clopidogrel Formulations Does Mylan Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CLOPIDOGREL/ACIDE ACETYLSALICYLIQUE MYLA | $750.0K | 15 |
| CLOPIDOGREL E ACIDO ACETILSALICILICO MYL | $450.0K | 9 |
| HARMLESS MEDICINES, CLOPIDOGREL/ACIDE AC | $350.0K | 7 |
| HARMLESS MEDICINES, CLOPIDOGREL E ACIDO | $300.0K | 6 |
| CLOPIDOGREL / ACIDE ACETYLSALICYLIQUE MY | $250.0K | 5 |
| HARMLESS MEDICINES, CLOPIDOGREL E ACIDOACETILSALICILICO MYLAN 75 MG/100 MG 28 BL TAB 24,993 PACKS | $150.0K | 3 |
| HARMLESS MEDICINES, CLOPIDOGREL E ACIDOACETILSALICILICO MYLAN 75 MG/100 MG 28 BL TAB 25,440 PACKS | $150.0K | 3 |
| CLOPIDOGREL ACIDE ACETYLSALICYLIQUE MYLAN 75 MG 75 MG 30BL TAB PACKS 54317 | $100.0K | 2 |
| CLOPIDOGREL/ACIDE ACETYLSALICYLIQUE VIATRIS 75 MG/75 MG 30BL TAB (Packs : 3 X 10'S BLISTER) (54272 PACKS X 3 | $100.0K | 2 |
| CLOPIDOGREL E ACIDO ACETILSALICILICO MYLAN 75 MG/100 MG 28 BL TAB (26437 PACKS X4 X 7S = 740236 NOS)NOS | $55.3K | 3 |
Mylan Laboratories Limited exports 39 distinct Clopidogrel formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CLOPIDOGREL/ACIDE ACETYLSALICYLIQUE MYLA with 15 shipments worth $750.0K.
How Does Mylan Laboratories Limited Compare to Nearest Clopidogrel Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | SANDOZ PRIVATE LIMITED | $5.3M | 105 | 7 | $50.0K |
| 15 | MICRO LABS LIMITED | $5.2M | 217 | 20 | $24.0K |
| 10 | MYLAN LABORATORIES LIMITED ★ | $4.3M | 86 | 3 | $50.0K |
| 13 | DR REDDYS LABORATORIES LIMITED | $3.9M | 78 | 6 | $50.0K |
| 12 | UNICHEM LABORATORIES LIMITED | $3.3M | 66 | 2 | $50.0K |
Mylan Laboratories Limited ranks #10 among 416 Indian Clopidogrel exporters. Average shipment value of $50.0K compared to the market average of $320.2K. The closest competitors by value are SANDOZ PRIVATE LIMITED and MICRO LABS LIMITED.
Which Indian Ports Ship Clopidogrel Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 576 | 9.5% |
| HYDERABAD ICD (INSNF6) | 490 | 8.1% |
| HYDERABAD ICD | 408 | 6.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 366 | 6.1% |
| SAHAR AIR | 350 | 5.8% |
| JNPT/ NHAVA SHEVA SEA | 295 | 4.9% |
| DELHI AIR CARGO ACC (INDEL4) | 267 | 4.4% |
| DELHI AIR | 256 | 4.2% |
Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Clopidogrel Exports
Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.
In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.
Mylan Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.
The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.
About Mylan Laboratories Limited
Mylan Laboratories Limited exports 91 products worth $634.8M. Beyond Clopidogrel, top products include Tenofovir, Pantoprazole, Valsartan, Ritonavir, Trastuzumab. View the complete Mylan Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Clopidogrel — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Clopidogrel shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 86 individual customs records matching Mylan Laboratories Limited exporting Clopidogrel, covering 39 formulations to 3 countries via 19 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 137+ countries, 1,234+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Clopidogrel Export Data from Mylan Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Mylan Laboratories Limited's Clopidogrel exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Mylan Laboratories Limited
Full Company Profile →
91 products · $634.8M total trade · 26 categories
Clopidogrel Stats
Company Overview
Top Products by Mylan Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Mylan Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Clopidogrel. For current shipment-level data, contact TransData Nexus.